OneDigital Investment Advisors LLC Reduces Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

OneDigital Investment Advisors LLC cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.4% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 13,516 shares of the medical research company’s stock after selling 619 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $8,361,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the stock. BDF Gestion bought a new position in shares of Thermo Fisher Scientific in the second quarter worth $6,368,000. Nisa Investment Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 6.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 140,708 shares of the medical research company’s stock valued at $87,093,000 after acquiring an additional 8,180 shares in the last quarter. Seven Eight Capital LP bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at about $1,161,000. ORG Partners LLC increased its position in shares of Thermo Fisher Scientific by 216.6% in the second quarter. ORG Partners LLC now owns 1,640 shares of the medical research company’s stock worth $890,000 after purchasing an additional 1,122 shares during the last quarter. Finally, CWM LLC raised its stake in Thermo Fisher Scientific by 9.5% in the second quarter. CWM LLC now owns 18,358 shares of the medical research company’s stock valued at $10,152,000 after purchasing an additional 1,590 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $533.02 on Friday. The business’s 50 day moving average price is $589.87 and its 200-day moving average price is $583.04. Thermo Fisher Scientific Inc. has a fifty-two week low of $463.99 and a fifty-two week high of $627.88. The firm has a market cap of $203.88 billion, a P/E ratio of 33.42, a P/E/G ratio of 3.58 and a beta of 0.79. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. During the same period in the prior year, the business earned $5.69 EPS. The company’s revenue for the quarter was up .2% on a year-over-year basis. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Insider Activity

In other news, CEO Marc N. Casper sold 9,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $552.86, for a total value of $4,975,740.00. Following the completion of the transaction, the chief executive officer now owns 14,608 shares of the company’s stock, valued at $8,076,178.88. The trade was a 38.12 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the transaction, the executive vice president now directly owns 16,663 shares of the company’s stock, valued at $9,333,946.08. This trade represents a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 37,150 shares of company stock worth $20,651,865 in the last quarter. 0.34% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently commented on TMO. Redburn Atlantic assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, October 14th. They issued a “buy” rating and a $680.00 price target on the stock. Royal Bank of Canada lowered their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Bernstein Bank upped their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a report on Tuesday, October 22nd. Robert W. Baird dropped their target price on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Finally, Morgan Stanley increased their price target on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a research report on Friday, September 20th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $649.33.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.